Patients randomly assigned to sequential treatment received fluorouracil @ mg/m ( @ ) , epirubicin @ mg/m ( @ ) , and cyclophosphamide @ mg/m ( @ ) ( FEC-@ ) on day @ of a @-day cycle for four cycles followed by paclitaxel @ mg/m ( @ ) and trastuzumab @ mg/kg ( after a @ mg/kg loading dose ) once per week for @ weeks , while those randomly assigned to the concurrent treatment group received paclitaxel and trastuzumab once per week for @ weeks followed by four cycles of FEC-@ ( on day @ of each @-day cycle ) and once-weekly trastuzumab , in the same doses as the sequential group .